**Amendment No. 1**

**to the framework agreement on the supply of laboratory material**

**- Part 5: Reagent kits for genomic analysis, sample preparation and purification from 2025 to 2026**

**1. BUEYR:**

Company name/Name:  **Institute of Applied Biotechnologies a.s.**

Headquarters:     Kramolínská 955, 199 00 Prague 9

Represented by:     RNDr. Petr Kvapil, Chairman of the Board

Company ID No.:     27225712

VAT No.:         CZ27225712

Bank details:      UniCredit Bank Czech Republic and Slovakia, a.s.

            Account number: 1388101477/2700

The company is registered in the Commercial Register maintained by the Municipal Court in Prague, Section B, Insert 9836.

*(hereinafter referred to as the "Buyer")*

and

**2. SELLER:**

Business name/Name:  **Bionano Genomics, Inc.**

Registered office/Place of business:  9540 Towne Centre Drive, Suite 100,

San Diego , CA 92121, USA

Business registration name:  Bionano Genomics, Inc.

ID number:  Tax ID: 261756290

DUNS No: 145913666

Represented by:  Dr Erik Holmlin

Bank account:  East West Bank

Account No: 92804535 - ABA No: 322070381

- SWIFT No: EWBKUS66XXX

*(hereinafter referred to as the "Seller")*

*(hereinafter collectively referred to as the " Parties ")*

**Article I. – Introductory Provisions**

1. The Parties confirm that on September 8, 2025, they entered into the above-specified Framework Agreement (hereinafter referred to as the “Framework Agreement”).

**Article II. – Change of list of products**

1. In accordance with Article VII, Clause 7 of the Framework Agreement, the Parties have agreed to amend the list of products due to changes in the Seller’s product range, which resulted in changes to catalogue numbers and the discontinuation of certain products. The updated list of products forms Appendix no. 1 to this Amendment and replaces the original Appendix to the Framework Agreement.

**Article III – Final Provisions**

1. This Amendment no. 1 forms an integral part of the Framework agreement.
2. This Amendment no. 1 introduces changes to the Framework Agreement as described in Article II, Clause 1 of this Amendment. The Framework Agreement remains valid and effective in all other provisions not affected by this Amendment.
3. This Amendment No. 1 shall become valid and effective on the date of signature by both Parties.
4. This Amendment shall be published in the Contract Register.
5. This Amendment is executed as an electronic original.

**Date:** **Date:**

**Buyer:** **Seller:**

Institute of Applied Biotechnologies a.s. Bionano Genomics, Inc.

**Name, Surname, function:** **Name, Surname, function:**

RNDr. Petr Kvapil, Erik Holmlin

Chairman of the Board of Directors President and CEO, Bionano

**Signature:** **Signature:**

 ……………………………………. ……………………………………